Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide PK in Renal Impairment
NCT02014259Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide plasma concentration time curve. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02014259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014259.